Curis Provides Third Quarter 2024 Business Update [Yahoo! Finance]
Curis, Inc. (CRIS)
Last curis, inc. earnings: 11/1 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.curis.com
Company Research
Source: Yahoo! Finance
biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the quarter ended September 30, 2024 "We continue to make excellent progress across our clinical programs. We are especially excited about the recent R/R PCNSL data released in September which continue to demonstrate the activity of emavusertib in combination with ibrutinib in salvage-line patients and that the CR/CRu responses appear to be durable," said James Dentzer , Curis Chief Executive Officer. "We are also excited to present additional clinical data in our TakeAim Leukemia study next month at ASH. We believe the positive momentum as we finish the year sets us up well for 2025." Third Quarter 2024 and Recent Operational Highlights Emavusertib (IRAK4 Inhibitor) TakeAim Lymphoma In September, at the 3 rd Annual IRAK4 Symposium in Cancer, the Company released preliminary efficacy data
Show less
Read more
Impact Snapshot
Event Time:
CRIS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRIS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRIS alerts
High impacting Curis, Inc. news events
Weekly update
A roundup of the hottest topics
CRIS
News
- Curis, Inc. (NASDAQ: CRIS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Curis Announces Additional Data from TakeAim Leukemia StudyPR Newswire
- Curis, Inc. (NASDAQ: CRIS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Curis Inc (CRIS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ... [Yahoo! Finance]Yahoo! Finance
- Curis Provides Third Quarter 2024 Business UpdatePR Newswire
CRIS
Earnings
- 11/14/24 - Beat
CRIS
Sec Filings
- 11/14/24 - Form 10-Q
- 11/14/24 - Form 8-K
- 11/13/24 - Form SC
- CRIS's page on the SEC website